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Abstract
Background Myosteatosis has been reported to be a novel biomarker that could predict survival outcomes in patients with
colorectal cancer. However, results have been conflicting. This systematic review and meta-analysis aimed to evaluate the
long-term impact of myosteatosis on the survival of these patients.
Methods A systematic search of PubMed, Embase, and Cochrane up to 27 November 2019 generated 7022 records. Studies
that reported hazard ratio (HR) for overall survival, cancer-specific survival, or disease-free survival based on myosteatosis or
radiodensity were included. A total of 110 full-text articles were considered for inclusion, and 14 were selected for qualitative
analysis. Inverse variance method was used with random effects model for data analysis.
Results The total number of enrolled patients included in the meta-analysis was 6518 for univariate and 8572 for multivar-
iate HR analysis, from 12 and 10 studies, respectively. Patients with myosteatosis had a significant increase in overall mortality
compared with non-myosteatosis patients by both univariate analysis [HR 1.38, 95% confidence interval (CI) 1.21 to 1.58,
P < 0.00001] and multivariate analysis (HR 1.55, 95% CI 1.23 to 1.96, P < 0.00001). In subgroup analysis based on studies that
reported HRs of both sarcopenia and myosteatosis, the negative effect of myosteatosis on overall survival was independent of
sarcopenia using univariate values (sarcopenia HR 1.48, 95% CI 1.14 to 1.91, P = 0.003 vs. myosteatosis HR 1.51, 95% CI 1.17 to
1.96, P = 0.002) and multivariate values (sarcopenia HR 1.28, 95% CI 1.09 to 1.49, P = 0.002 vs. myosteatosis HR 1.38, 95% CI
1.07 to 1.80, P = 0.001).
Conclusions This meta-analysis demonstrates that myosteatosis is associated with worse overall survival in patients with
colorectal cancer. More investigation is needed to standardize the measurement protocol for myosteatosis and to further
optimize its prognostic power for colorectal cancer patients.
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Introduction
Post-operative tumour stage or pre-operative disease dissem-
ination status for unresectable patients has traditionally been
used to determine the prognosis of the cancer patients.1
However, there has been an increasing interest on the extent
of host tumour response as an additional indicator of cancer
prognosis, such as host systemic inflammation and body
composition of macromolecules.2–4 Over the last decade,
the concept of sarcopenia has gained grounds in the oncology
field, where sarcopenia identified pre-operatively was found
to be associated with adverse oncological outcomes and
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increased morbidity for surgical patients.5–7 Similarly, evalua-
tion of qualitative measures of skeletal muscles in computed
tomography (CT), which is expressed in various terms such as
myosteatosis, skeletal muscle radiodensity (SMD), or skeletal
muscle radiation attenuation, has also been increasingly stud-
ied, particularly in patients with colorectal cancer (CRC).8–10
Because these terms refer to the same physiological changes
of skeletal muscle, we have chosen to use the term
‘myosteatosis’ throughout this manuscript for consistency.
Martin et al. 11 defined myosteatosis as a mean value less
than 41 Hounsfield unit (HU) for patients with body mass in-
dex (BMI) less than 25 and a mean value less than 33 for a
BMI greater than 25, using CT-defined cross-sectional skeletal
muscle measurements at the third lumbar vertebra. Using
these cut-offs, many investigators identified that patients
with low SMD were associated with higher overall and
CRC-specific mortality when compared with those with nor-
mal SMD levels.4,8,12 A recent study has shown that
myosteatosis is associated with shorter survival in multiple
cancer types.13 However, there were other studies not show-
ing clear association between myosteatosis and survival for
patients with CRC.8,14 To reconcile these findings and to con-
solidate the role of myosteatosis as a possible prognostic fac-
tor in CRC, a review of the existing evidence thus far seemed
timely and appropriate.
Thus, we performed an in-depth systematic review and
meta-analysis to investigate the long-term impact of
myosteatosis or SMD on survival in patients with CRC.
Methods
All procedures used in this study were performed according
to the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses guidelines.15
Data sources and searches
We included articles that reported on human studies pub-
lished in the English language up to 27 November 2019 from
PubMed, Embase, and Cochrane Central. The full list of
search terms by category is included in Supporting Informa-
tion, Appendix S1, and the search strategy with the number
of search results is provided in Appendix S2.
Study selection
The list of retrieved studies was initially screened by titles, ab-
stracts, and availability of full-text article. J. K. and C. M. L.
screened full-text articles of relevant studies independently,
and discrepancies were resolved by discussion. Studies were
selected on several inclusion criteria. First, the patient
population consisted of CRC patients. Second, the primary
outcomes were measured and reported as hazard ratios
(HRs) of overall survival (OS) and/or disease-free survival
(DFS) or cancer-specific survival (CSS) with myosteatosis or
radiodensity as one of the variables. Third, previously pub-
lished definitions of myosteatosis were used and identified
based on decreased mean HU on radiodensity, instead of
assessing changes in radiodensity pre-operative or
post-operative stages. Studies that did not contain primary
data, such as those only available as conference abstracts, ed-
itorials, or commentaries, were excluded. When the same pa-
tient cohort was used in multiple publications, the study that
included more appropriate data for our study was included.
Data extraction
We extracted all mean HRs with 95% confidence interval (CI)
for OS, DFS, and/or CSS separately, along with measurement
method, location of the CT scan, and the definition of
myosteatosis including references. Other clinical data col-
lected from full-text articles included study design, study site,
number of patients enrolled, basic patient demographics (age
and gender), software used for muscle density measurement,
and the time point of CT exam. Cohen’s inter-rater κ statistics
for inclusion agreement was 0.620 (95% CI 0.320 to 0.919),
with strength of agreement considered ‘good’.16
Definition of myosteatosis
Myosteatosis in most studies was defined as SMD <41 HU in
patients with BMI <25 kg/m2 and <33 in patients with
BMI ≥25 mg/m2, which was suggested by Martin et al.11
For study by Dolan et al.17 myosteatosis was defined by Xiao
et al.10 as <35.5 HU in men and <32.5 HU in women. Simi-
larly, most studies included in our meta-analysis assessed
the area of total skeletal muscle from a single image taken
at the third lumbar vertebra, except Okugawa et al.14 which
used intramuscular adipose tissue content (IMAC) calculated
from mean CT value of region of interest (ROI) of multifidus
muscle (HU) divided by mean CT value of ROI of subcutane-
ous fat in HU and assessed the superior aspect of fourth lum-
bar vertebra and the psoas muscle. For the particular study,
high IMAC using sex-specific median values was used to de-
fine myosteatosis.14 The variations in the definition of
myosteatosis used in the included study are summarized in
Table 1. In this study, we included both search terms of
‘low radiodensity’ and ‘myosteatosis’ to identify the patient
cohorts, and they refer to the same methods of HU measure-
ments within CT images. To avoid confusion, we have used
‘myosteatosis’ throughout the manuscript to describe find-
ings that were identified as ‘myosteatosis’ or ‘low SMD’.
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Data synthesis and statistical analysis
Results were grouped separately according to the final out-
comes by HR for myosteatosis with 95% CI of OS, CSS, or
DFS. A meta-analysis was performed using a random effects
model because of assumed heterogeneity between studies.18
Random effects model allows the true effect size to differ
from study to study, as it assumes that studies included in
the analysis are random samples of all possible studies that
meet the inclusion criteria.19 This may be more reflective of
the current meta-analysis as different studies recruited pa-
tients of varying cancer stage, ethnicity, gender proportions,
and co-morbidities. We compared HR values available for
OS, CSS, and DFS by univariate vs. multivariate analysis, and
because most HR values were available for OS (12 studies
for univariate values and 10 studies for multivariate values,
respectively, as outlined in Table S1), we focused our
meta-analysis of myosteatosis on OS.
For the data analysis, inverse variance method was used to
obtain pooled HRs and 95% CIs. Statistical analysis was
performed using the Review Manager software (RevMan,
Version 5.3 for Windows, Oxford, UK; the Cochrane Collabo-
ration, 2014), to calculate the summary effect size, 95% CI,
and P-values of random and fixed effect models. Forest plots
were used to visualize the results, and heterogeneity
between studies was assessed using the I2 statistic and the
P-value from the χ2-based Cochran’s Q test. I2 values reflect
the percentage of variation among studies attributed to het-
erogeneity rather than to chance. Thus, I2 values higher than
25%, 50%, or 75% were considered to describe low, moder-
ate, or high heterogeneity, respectively,20 and χ2 < 0.10
was used to define statistically significant heterogeneity.21
Assessment of publication bias
To check for publication bias, we generated funnel plots of
log[HR] against its standard error and used Egger’s regression
asymmetry test. Where the asymmetry was found, the po-
tential impact of the publication bias was assessed by the
Duval and Tweedie non-parametric ‘trim-and-fill’ method.22
Meta-Essentials (Version 1.4; Rotterdam, The Netherlands:
Erasmus Research Institute of Management) was used to
perform the Egger’s regression asymmetry test.23 All tests
of significance were two sided, and P-values <0.05 were
considered to be statistically significant.
Quality assessment
The Newcastle–Ottawa scale scoring for cohort studies for
the meta-analysis of myosteatosis in CRC has already been
published.13,24 The Quality in Prognosis Studies (QUIPS) tool
was used to assess the quality of the methodology of
included studies, by considering each of the domains outlined
by Hayden et al.25 and rating for whether the study was con-
ducted in a way to limit the potential bias (yes, no, partly, or
unclear). In this systematic review, studies that were identi-
fied as having an overall high risk of bias were those that
did not have clear criteria for myosteatosis and did not per-
form statistical analyses such as multivariate analyses to ac-
count for potential confounding factors. The Grading of
Recommendations, Assessment, Development and Evaluation
(GRADE)26 was performed to assess the quality of evidence
for the effect of myosteatosis on the OS of CRC patients using
the GRADEPro GDT software (McMaster University, 2015, de-
veloped by Evidence Prime, Inc).
Results
Identification of studies and study characteristics
Our search on 27 November 2019 retrieved 7751 publications
(3732 from Embase, 666 from PubMed, and 3353 from
Cochrane) (Figure 1). After removal of duplicates, 7022 re-
cords were screened independently by the two authors
(J. K. and C. M. L.), which led to exclusion of 6847 by title re-
view, 65 abstracts, 11 review articles, editorials, and com-
ments, 72 studies with no data on myosteatosis, and 13
with no data on the association between myosteatosis and
patient survival. A total of 110 full-text articles were consid-
ered for inclusion. After full-text review of each article, 14
were selected for qualitative analysis. Among 14 included
studies, nine studies were retrospective, while four studies
were prospective,9,27–29 and one study was a post hoc analy-
sis of two non-randomized Phase II trials.30
Included studies and patient characteristics
All patients included in the study had been diagnosed with
CRC, mostly between Stages I–III (seven studies) and Stages
I–IV (five studies), and also at metastatic (one study) or
chemorefractory status (one study). The number of patients
categorized as having myosteatosis ranged from 42 to 966
or 19–78% of the study cohort, with total number of patients
included in the meta-analysis being 6518 for univariate and
8572 for multivariate HR analysis for OS. Patients with
myosteatosis, excluding studies that did not provide a clear
definition or cut-offs for myosteatosis to determine the pre-
cise size of the myosteatosis cohort, totalled to be 3059 for
univariate and 3401 for multivariate HR analysis. Time at
which the CT was analysed was mostly at pre-operative eval-
uation, but where specified, varied between 21 days before
surgery31 to within 3 months of surgery17 or within 4 months
of chemotherapy or radiotherapy.9
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Myosteatosis and overall survival in colorectal
cancer
Patients with myosteatosis had a significant increase in the
overall mortality compared with non-myosteatosis patients
by both univariate analysis (HR 1.38, 95% CI 1.21 to 1.58,
P < 0.00001) (Figure 2) and multivariate analysis (HR 1.55,
95% CI 1.23 to 1.96, P < 0.00001) (Figure 3A). This indicates
that myosteatosis has an independent prognostic significant
effect on OS. However, a fairly large dispersion was observed
Figure 1 Flow diagram depicting the selection process for studies. HR, hazard ratio.
Figure 2 Meta-analysis of univariate results reporting impact of myosteatosis on overall survival in patients with colorectal cancer using the random
effects model. CI, confidence interval; df, degrees of freedom; IV, inverse variance; SE, standard error.
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in both plots (I2 = 92% and 80%, respectively). By funnel plot,
publication bias was detected for univariate analysis (Egger
P = 0.004) (Figure S2A) but not for multivariate analysis (Egger
P = 0.125) (Figure S2B). Studies that did not show significance
in the forest plot32–34 in Figure 2 were largely those with no
clear cut-off or definition for myosteatosis and which scored
very poorly in the QUIPS assessment. For example, in Looijaard
et al., 33 muscle density measured in HU without any cut-off
for myosteatosis was used for the HR calculation, which
yielded an insignificant HR value.
Myosteatosis and cancer-specific survival and
disease-free survival in colorectal cancer
We identified five studies that reported adjusted data on the
effect of myosteatosis on CSS. Meta-analysis of the five ad-
justed studies showed a significant increase in CRC-specific
mortality with the presence of myosteatosis for random
effects model (HR 1.69, 95% CI 1.43 to 2.00, P < 0.00001)
(Figure 3B). Heterogeneity was low among these studies
(I2 = 20%). We also performed a meta-analysis of DFS HR
values, but interestingly, there was no effect of myosteatosis
on DFS (HR 1.00, 95% CI 0.95 to 1.05, P = 0.88) (Figure S1).
Comparison of myosteatosis and sarcopenia in
colorectal cancer
Using nine and seven studies that reported the impact of both
sarcopenia and myosteatosis in their study cohort by
univariate and multivariate analysis of HR for OS, respectively
(Table 2), we found that sarcopenia and myosteatosis had
independent negative effects on OS. Figures 4 and 5 show
the negative effect of sarcopenia and myosteatosis using
univariate values (sarcopenia HR 1.48, 95% CI 1.14 to 1.91,
P = 0.003 vs. myosteatosis HR 1.51, 95% CI 1.17 to 1.96,
P = 0.002) and multivariate values (sarcopenia HR 1.28, 95%
CI 1.09 to 1.49, P = 0.002 vs. myosteatosis HR 1.38, 95% CI 1.07
to 1.80, P = 0.001) (Figures 4 and 5). Two studies 9,31reported the
effect of having both sarcopenia and myosteatosis on patient sur-
vival (HR2.02,95%CI1.65 to2.47andHR2.24,95%CI1.63 to3.09,
respectively).
Quality assessment
The 14 studies were assessed for each of the six domains of the
QUIPS tool, where a rating of ‘yes’ means that the study was
designed and conducted to sufficiently limit the potential
biases within that domain. ‘Unclear’ denotes that the answer
Figure 3 Meta-analysis of multivariate results reporting impact of myosteatosis on (A) overall survival and (B) cancer-specific survival in patients with
colorectal cancer using the random effects model. CI, confidence interval; df, degrees of freedom; IV, inverse variance; SE, standard error.
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to the item was not reported clearly, and ‘partly’ similarly indi-
cates that the item was not fully addressed. Most studies were
retrospective cohort studies from prospectively maintained
databases, with well-defined collection period and detailed
description of the patient populations. However, one study32
did not provide sufficient baseline characteristics of the cohort,
and four studies either did not provide clear definition of
myosteatosis32–34 or had very small proportion of the study
Table 2 Studies that report both sarcopenia and myosteatosis and the respective HR for OS













Charette et al.30 2.06 (1.45 to 2.93) 1.54 (1.09 to 2.18) 1.49 (1.04 to 2.15) 1.80 (1.24 to 2.61)
Deng et al.32 0.93 (0.84 to 1.02) 0.99 (0.95 to 1.04) NA NA
Dolan et al.17 1.74 (1.21 to 2.49) 1.84 (1.25 to 2.72) 1.50 (1.04 to 2.18) 1.42 (0.98 to 2.05)
Hopkins et al.31 2.01 (1.67 to 2.50) 2.03 (1.61 to 2.54) 1.45 (1.15 to 1.84) 1.54 (1.19 to 1.98) 2.24 (1.63 to 3.09)
Kroenke et al.9 NA NA 1.30 (1.07 to 1.57) 1.63 (1.30 to 2.05) 2.02 (1.65 to 2.47)
Looijaard et al.33 0.953 (0.812 to 1.119) 0.814 (0.694 to
0.955)
0.998 (0.840 to 1.187) 0.918 (0.771 to 1.093)
Malietzis et al.8 1.77 (1.32 to 2.38) 1.42 (1.09 to 2.50) 1.70 (1.25 to 2.31) NA
McSorley et al.4 1.40 (0.88 to 2.24) 2.47 (1.49 to 4.10) NA 2.29 (1.38 to 3.81)
Okugawa et al.14 NA NA NA NA
Sabel et al.34 NA 0.97 (0.95 to 1.00) NA NA
Sueda et al.12 2.14 (0.99 to 4.97) 2.42 (1.10 to 5.84) 2.29 (1.04 to 5.41) 2.94 (1.32 to 7.17)
Van Baar et al.28 NA NA NA 1.91 (1.53 to 2.38)
Van Vugt et al.29 1.35 (1.03 to 1.76) 1.75 (1.29 to 2.36) 1.06 (0.80 to 1.42) 0.91 (0.65 to 1.29)
CI, confidence interval; HR, hazard ratio; OS, overall survival; NA, not applicable.
Figure 4 Meta-analysis of univariate results reporting impact of (A) sarcopenia and (B) myosteatosis by random effects model in studies that report
both findings in the same study cohort. CI, confidence interval; df, degrees of freedom; IV, inverse variance; SE, standard error.
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cohort with myosteatosis,30 which affected both study attri-
tion and prognostic factor measurement. Outcome measure-
ment was judged to be clearly defined by all studies for
overall mortality. For confoundingmeasurement, minimum re-
quirements were set as that the results were adjusted for age,
gender, and disease stage. Studies adjusted for less or different
factors were denoted as ‘partly’.14,27,33,34 Regarding statistical
approach, four studies did not include multivariate analyses
and were judged as with high potential for this bias.8,14,32,34
One study was noted as ‘partly’ for the statistical approach
domain33 as muscle density without cut-off was used in the
analysis. Three studies were judged to be at an overall high risk
of bias,32–34 given inadequate definition or measurement of
myosteatosis and ‘partly/unclear’ or high risk of bias for
the confounding measurement and statistical approach
(Table S2). The GRADE assessment of studies included in the
meta-analysis is provided in Table 3, which gave ‘Low’ score
on the overall certainty of evidence as there were no random-
ized controlled trial studies and mostly retrospective studies.
Discussion
This systematic review and meta-analysis demonstrate that
myosteatosis measured in pre-treatment periods could be
used as an independent predictor of worse survival outcomes
in patients with CRC.
Sarcopenia has been increasingly recognized not only as a
prognosticator of adverse outcomes but also as a predictor
of post-operative morbidity.7,31,32,35–37 Even in CRC, the neg-
ative impact of sarcopenia on survival has been increasingly
investigated.38–40 Intramuscular fat accumulation, referred
to as ‘myosteatosis’, is an early change within the muscle
architecture, associated with significantly decreased muscle
quality.41 In addition to the loss of muscle mass, however,
the concept of sarcopenia has been extended to include mus-
cle quality and function.42 Recent studies looking at the effect
of skeletal muscle mass and/or composition on the survival of
CRC patients have found that patients with both sarcopenia
and myosteatosis have worse OS than those patients with
sarcopenia or myosteatosis alone.9,31 However, there are also
studies reporting no prognostic impact of myosteatosis in pa-
tients with CRC,27,34 which prompted us to look into whether
myosteatosis was an independent risk factor as in the case
for sarcopenia. Although there was a large meta-analysis
looking at myosteatosis and prognosis in multiple cancer
types,13 detailed analysis is still required for CRC because of
its prevalence and controversies of the outcomes.
The exact pathogenesis of myosteatosis or its relationship
to sarcopenia is not clearly understood, though some clinical
data suggest that there may be a common mechanism to
Figure 5 Meta-analysis of multivariate results reporting impact of (A) sarcopenia and (B) myosteatosis by random effects model in studies that report
both findings in the same study cohort. CI, confidence interval; df, degrees of freedom; IV, inverse variance; SE, standard error.
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sarcopenia and myosteatosis. Systemic inflammatory
response in patients with CRC, for example, has been associ-
ated with both sarcopenia and myosteatosis, with high
neutrophil-to-lymphocyte ratio being an independent predic-
tor of reduced muscle mass (odds ratio 1.78, 95% CI 1.29 to
2.45) and myosteatosis (odds ratio 1.60, 95% CI 1.03 to
2.45).8 It is thought that anti-tumour proteins and the
pro-inflammatory cytokines such as interleukin-1β43 against
cancer contribute to systemic inflammation and muscle
wasting, cachexia, and sarcopenia.44 The basic mechanism
of myosteatosis and its relation to survival outcome might
be important to identify the most appropriate intervention
at the time of diagnosis such as anti-inflammatory medica-
tions, which may improve long-term survival outcomes,31
and future interventional studies such as means of increasing
muscle mass before surgery may be helpful. The exact
pathogenesis of myosteatosis and how it differs in different
cancer types are also subjected to further investigation.
Although our analysis revealed the association of
myosteatosis with worse survival, there are several issues
on the use of myosteatosis as a significant and standardized
prognostic factor in patients with CRC. Firstly, there is cur-
rently no unified or validated consensus on the definition of
myosteatosis. Most of the included studies used <41 HU in
patients with BMI <25 kg/m2 and <33 in patients with
BMI ≥25 mg/m2 as a cut-off value of radiodensity,11 but
others have also used <35.5 HU in men and <32.5 HU in
women10 or IMAC calculation,14 or their own criteria
(22.5 HU).30 The clinical significance of myosteatosis may vary
depending on which criteria are used, and future studies
should correlate myosteatosis with measurements of muscle
function. For instance, in a study using their own cut-off of
22.5 HU, muscle density was found to be an important prog-
nostic factor in the multivariate analysis (HR 1.8, 95% CI 1.24
to 2.61), but when using the cut-off values originated from
Martin et al.11 which were generated from mixed group of
cancers and mostly from poor prognosis, low muscle density
was not associated with OS (HR 1.25, 95% CI 0.89 to 1.77).30
Even in our study, for univariate analysis (Figure 2), the three
studies with HR values close to 1 or on the side of favouring
myosteatosis were those without clear criteria for
myosteatosis. Secondly, the HU may vary depending on the
phase of the CT used for measurement. One study reported
that mean SMD in the unenhanced phase is significantly
lower than that measured in the arterial and portal venous
phase [unenhanced phase (30.9 ± 8.0 HU) vs. arterial
(38.0 ± 9.9 HU) or portal venous (38.7 ± 9.2 HU) phase (both
P < 0.001)].45 In this meta-analysis, comparison of the CT
protocol or phase could not be performed because of lack
of such information. These limitations may render
cross-comparison between different studies challenging.
There are also several limitations to our study. Not every
study looking at the OS of CRC patient had measured SMD
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exclusion for the purpose of our study. Similarly,
myosteatosis was often not the main focus of many of the
studies included, which means that the patient demographics
were often not sufficiently stratified within the study popula-
tion to identify potential confounding variables, other than a
‘yes/no’ on the presence of myosteatosis and a report on the
final survival outcome in a form of meta-analysis. Other
sources of variations among studies may include different
cancer stage, race, and gender ratio of the patient
population.
In this meta-analysis, studies including OS were more
represented than those studies reporting CSS or DFS.
Meta-analysis of studies that report the impact of both
sarcopenia and myosteatosis in their study, myosteatosis
had negative effects on OS independent from sarcopenia,
by both univariate and multivariate analyses. Interestingly,
however, myosteatosis did not have an effect on DFS, un-
like OS or CSS. This could suggest that myosteatosis does
not reflect the aggressiveness of CRC but acts mainly as
an indicator of overall fragility of the host. Because
myosteatosis increases with age and is known to be associ-
ated with obesity and diabetes,46,47 it would be important
to ensure matched analysis of patients in future studies.
It still remains uncertain whether the worse survival out-
comes for patients with myosteatosis are associated with
aggressive tumour behaviour, impaired host immune de-
fence, or a combination of both as its possible mechanism.
Although an investigation of this question was beyond the
scope of our study, this phenomenon might be useful in
elucidating the association of myosteatosis with worse out-
comes in patients with CRC.
We hereby report the association between myosteatosis
and OS in CRC and that myosteatosis is an independent pre-
dictor of worse survival. More investigation is needed to stan-
dardize the measurement protocol for myosteatosis and to
further optimize its prognostic power by cancer stage and pa-
tient demographics for CRC patients.
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